Insulin: A Voice for ChoiceIn the early 1980s synthetic 'human' insulin produced by recombinant DNA technology came onto the market. Despite an acknowledgment by the manufacturers regarding the potential dangers of 'human' insulin they soon began to withdraw bovine and porcine insulin from markets all over the world, and promoted more expensive 'human' insulins as a superior replacement. Diabetics had no option but to effectively switch to the new synthetic insulins and often they received little or no information about their potentially life-threatening side effects. In the first part of this book the author provides fundamental information about insulin therapy and its history. A detailed discussion of the hazards confronting some diabetic patients when using 'human' insulin follows. Due to more pronounced hypoglycemia symptoms animal insulin can be regarded as safer than 'human' insulin for 10-20% of diabetic patients. The last part of this publication looks at the pharmaceutical industry's decision to withdraw animal insulin from the market and describes the struggles of a new global movement to secure its continued availability. This book not only provides potentially vital background information for those who depend on insulin, but also deserves the attention of professionals who prescribe or distribute this medication. It can also serve as a reference for patient advocates, relevant government departments and pharmaceutical companies. |
Contents
Overview of Insulin Therapy | 1 |
The History of Insulin | 10 |
Insulin Hypoglycemia | 14 |
Hazards of Human Insulin Hypoglycemia | 25 |
Research Demonstrating that Human andAnimal Insulins Are Not the Same | 44 |
Aggressive Marketing of Human Insulinand the Withdrawal of Animal Insulin | 54 |
Advocacy | 68 |
Outlook and Recommendations | 78 |
Other editions - View all
Common terms and phrases
accidents Actrapid adverse reactions advocacy amino acids analogue insulins animal insulin bedtime Berger Bern blood glucose levels blood sugar blood sugar levels British National Formulary cells cemia clinical dead-in-bed syndrome death Diabetes Association diabetes mellitus diabetic patients diabetologists doctors dose driving drug effects Egger Eli Lilly glucagon HbA1c human insulin Humulin hypo hypogly hypoglyce hypoglycemia unawareness hypoglycemic episodes hypoglycemic events hypoglycemic reactions IDDT increased insu insulin analogues insulin manufacturers insulin produced insulin pump insulin therapy insulin to human insulin treatment insulin-dependent diabetes International Diabetes Federation isophane kinetics Lancet mmol/l natural insulin Novo Nordisk occur oral pens physicians porcine insulin pork insulin problems Professor Teuscher recombinant DNA reported Semilente MC severe hypoglycemia subcutaneous Swiss Switzerland synthetic insulin type 1 diabetes type of insulin warning signs warning symptoms